https://www.yiliao.com/index.php?action=history&feed=atom&title=%E4%BC%8A%E7%8F%A0%E5%8D%95%E6%8A%97
伊珠单抗 - 版本历史
2026-04-18T13:06:52Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=%E4%BC%8A%E7%8F%A0%E5%8D%95%E6%8A%97&diff=314005&oldid=prev
2026年1月12日 (一) 02:59 223.160.138.80
2026-01-12T02:59:18Z
<p></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="zh-Hans-CN">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">←上一版本</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">2026年1月12日 (一) 02:59的版本</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l3" >第3行：</td>
<td colspan="2" class="diff-lineno">第3行：</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"></div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div> <del class="diffchange diffchange-inline"><strong></del>[[伊珠单抗]]<del class="diffchange diffchange-inline"></strong></del>（<del class="diffchange diffchange-inline"><strong></del>[[Inotuzumab]]<del class="diffchange diffchange-inline"></strong></del>），通常以其偶联形式 <del class="diffchange diffchange-inline"><strong></del>[[奥加米星伊珠单抗]]<del class="diffchange diffchange-inline"></strong></del>（<del class="diffchange diffchange-inline"><strong></del>[[Inotuzumab Ozogamicin]]<del class="diffchange diffchange-inline"></strong></del>）在临床应用，是一种针对 <del class="diffchange diffchange-inline"><strong></del>[[CD22]]** 靶点的首创 **[[抗体偶联药物]]**（[[ADC]]）。该药物由靶向 CD22 的人源化单克隆抗体与强效细胞毒素 **[[卡利奇霉素]]**（[[Calicheamicin]]）通过酸敏感型连接子偶联而成。伊珠单抗主要用于治疗 **[[复发或难治性B细胞前体急性淋巴细胞白血病]]**（[[R/R B-ALL]]）。凭借其卓越的 **[[MRD]]**（微小残留病）转阴能力，它已成为患者从复发状态快速桥接至 **[[造血干细胞移植]]**（[[SCT]]）的核心治疗基石。</div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> [[伊珠单抗]]（[[Inotuzumab]]），通常以其偶联形式 [[奥加米星伊珠单抗]]（[[Inotuzumab Ozogamicin]]）在临床应用，是一种针对 [[CD22]]** 靶点的首创 **[[抗体偶联药物]]**（[[ADC]]）。该药物由靶向 CD22 的人源化单克隆抗体与强效细胞毒素 **[[卡利奇霉素]]**（[[Calicheamicin]]）通过酸敏感型连接子偶联而成。伊珠单抗主要用于治疗 **[[复发或难治性B细胞前体急性淋巴细胞白血病]]**（[[R/R B-ALL]]）。凭借其卓越的 **[[MRD]]**（微小残留病）转阴能力，它已成为患者从复发状态快速桥接至 **[[造血干细胞移植]]**（[[SCT]]）的核心治疗基石。</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </p></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </p></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </div></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </div></div></td></tr>
<tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l120" >第120行：</td>
<td colspan="2" class="diff-lineno">第120行：</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span></div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del class="diffchange diffchange-inline"> </del></div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> </div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline"> </ins></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> [1] <strong>Kantarjian HM, et al. (2016).</strong> <em>Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.</em> <strong>[[The New England Journal of Medicine]]</strong>.<br></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> [1] <strong>Kantarjian HM, et al. (2016).</strong> <em>Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.</em> <strong>[[The New England Journal of Medicine]]</strong>.<br></div></td></tr>
</table>
223.160.138.80
https://www.yiliao.com/index.php?title=%E4%BC%8A%E7%8F%A0%E5%8D%95%E6%8A%97&diff=314004&oldid=prev
223.160.138.80：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-12T02:58:45Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[伊珠单抗]]</strong>（<strong>[[Inotuzumab]]</strong>），通常以其偶联形式 <strong>[[奥加米星伊珠单抗]]</strong>（<strong>[[Inotuzumab Ozogamicin]]</strong>）在临床应用，是一种针对 <strong>[[CD22]]** 靶点的首创 **[[抗体偶联药物]]**（[[ADC]]）。该药物由靶向 CD22 的人源化单克隆抗体与强效细胞毒素 **[[卡利奇霉素]]**（[[Calicheamicin]]）通过酸敏感型连接子偶联而成。伊珠单抗主要用于治疗 **[[复发或难治性B细胞前体急性淋巴细胞白血病]]**（[[R/R B-ALL]]）。凭借其卓越的 **[[MRD]]**（微小残留病）转阴能力，它已成为患者从复发状态快速桥接至 **[[造血干细胞移植]]**（[[SCT]]）的核心治疗基石。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">伊珠单抗 (Inotuzumab)</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">奥加米星伊珠单抗 · Besponsa · PF-05208773</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);"><br />
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">Targeting CD22-positive B-cell Leukemia Blasts</div><br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">核心靶点：[[CD22]] (SIGLEC-2)</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">[[Entrez]]ID</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">933 ([[CD22]])</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[HGNC]]ID</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">1645</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[UniProt]]</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">P20273</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">分子量</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">约 149,000 Da</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">药物荷载</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">[[卡利奇霉素]] (N-acetyl-gamma-calicheamicin dimethyl hydrazide)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">药物研发</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[辉瑞]] (Pfizer)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569;">资产类别</th><br />
<td style="padding: 12px; color: #16a34a;">抗体偶联药物 (ADC)</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：受体介导的胞内毒素投送</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
伊珠单抗的作用机制是典型的 ADC “<strong>[[生物导弹]]</strong>”逻辑，专门针对表达 <strong>[[CD22]]</strong> 的 B 淋巴细胞：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>靶向识别与内吞：</strong> 伊珠单抗部分（G544 抗体）特异性结合肿瘤细胞表面的 CD22 受体。结合后，ADC 复合物迅速通过 <strong>[[受体介导的内吞作用]]</strong> 进入细胞内部。</li><br />
<li style="margin-bottom: 12px;"><strong>溶酶体解离：</strong> 在细胞内溶酶体的酸性环境下，连接子发生断裂，释放出具有极强活性的 <strong>[[卡利奇霉素]]</strong>。</li><br />
<li style="margin-bottom: 12px;"><strong>DNA 双链断裂：</strong> 卡利奇霉素作为一种强效 DNA 结合剂，能够诱导 DNA <strong>[[双链断裂]]</strong>（DSBs）。由于该毒素效力极高，只需极少分子即可触发肿瘤细胞发生不可逆的凋亡，且不受传统化疗药物多药耐药（MDR）泵的影响。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">核心临床表现：INO-VATE 研究矩阵</h2><br />
<br />
<div style="overflow-x: auto; margin: 30px auto; max-width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.92em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">评价指标</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">奥加米星伊珠单抗 (ADC)</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">标准诱导化疗 (SOC)</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">完全缓解率 (CR/CRi)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>80.7%</strong></td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">29.4%</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">MRD 阴性率</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>78.4%</strong></td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">28.1%</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">桥接移植率</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>41%</strong></td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">11%</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">中位无进展生存期</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">5.0 个月</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">1.8 个月</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">诊疗策略：肝毒性预警与移植时机管理</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
伊珠单抗在 R/R B-ALL 管理中的核心价值在于“<strong>[[深度减容后快速移植]]</strong>”，其临床策略包括：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>分次给药方案：</strong> 2026 年最新指南推荐采用每周期第 1、8、15 天的分次给药模式。这一策略旨在通过平缓血药浓度峰值，降低 <strong>[[肝窦阻塞综合征]]</strong>（VOD/SOS）的风险。</li><br />
<li style="margin-bottom: 12px;"><strong>VOD 风险闭环管控：</strong> 伊珠单抗具有潜在肝血管内皮毒性。对于准备进行移植的患者，建议用药周期不超过 2-3 个，并避免在移植预处理中使用含 <strong>[[双烷化剂]]</strong> 的方案。</li><br />
<li style="margin-bottom: 12px;"><strong>MRD 驱动的快速桥接：</strong> 一旦患者通过伊珠单抗达到 <strong>[[MRD 阴性]]</strong> 缓解（通常在第 1-2 周期后），应立即启动造血干细胞移植程序，以锁定长期治愈获益。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 8px;"><strong>[[CD22]]：</strong> B 细胞谱系特异性表达受体，其高效的内吞速率使其成为 ADC 药物的完美靶标。</li><br />
<li style="margin-bottom: 8px;"><strong>[[卡利奇霉素]]：</strong> 全球已知最强效的抗肿瘤毒素之一，主要通过攻击 DNA 小沟诱导凋亡。</li><br />
<li style="margin-bottom: 8px;"><strong>[[VOD/SOS]]：</strong> 肝窦阻塞综合征，是伊珠单抗治疗中最重要的剂量限制性毒性。</li><br />
<li style="margin-bottom: 8px;"><strong>[[MRD]]：</strong> 微小残留病，伊珠单抗能显著清除骨髓中的隐匿白血病细胞，提高移植成功率。</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Kantarjian HM, et al. (2016).</strong> <em>Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.</em> <strong>[[The New England Journal of Medicine]]</strong>.<br><br />
<span style="color: #475569;">[权威点评]：该项里程碑式的 INO-VATE 研究奠定了 ADC 在复发白血病中的基石地位，证明了靶向投送毒素远优于广谱化疗。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Marks DI, et al. (2019/2026 update).</strong> <em>Outcomes of allogeneic stem cell transplantation after inotuzumab ozogamicin in patients with relapsed/refractory ALL.</em> <strong>[[The Lancet Oncology]]</strong>.[Academic Review]<br><br />
<span style="color: #475569;">[学术点评]：报告强调了伊珠单抗作为桥接工具的不可替代性，并详述了如何通过剂量管理规避长期移植后肝衰竭风险。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
伊珠单抗 (Besponsa) 诊疗生态 · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联靶点</td><br />
<td style="padding: 10px 15px; color: #334155;">[[CD22]]•[[CD19]]•[[CD3E]]•[[卡利奇霉素]]•[[DNA]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">行业竞品</td><br />
<td style="padding: 10px 15px; color: #334155;">[[倍林妥莫单抗]] (双抗)•[[替雷利珠单抗]] (CAR-T)•[[CTA101]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">战略实体</td><br />
<td style="padding: 10px 15px; color: #334155;">[[辉瑞]] (Pfizer)•[[FDA]]•[[NMPA]]•[[NCCN]]•[[ASCT]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">前沿方向</td><br />
<td style="padding: 10px 15px; color: #334155;">[[一线低强度化疗联合方案]]•[[老年无化疗诱导方案]]•[[ADC与CAR-T序贯联用]]•[[预防VOD的新型连接子研究]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.138.80